Clinical trial
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
NCT00082810 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00082810 |
|---|---|
| Title | Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer |
| Official title | A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug |
| Interventions | fulvestrant, tipifarnib |
| Enrollment | 33 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | May 19, 2004 |
| Last update posted | Nov 1, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: